Lumos signed binding agreements to raise capital of AU$8.0 million.

Lumos Diagnostics (ASX: LDX) has signed  agreements with SBC Global Investment Fund and Lind Global Fund II for investment in the Company of up to AU$8.0 million.

The Company has entered into binding convertible note agreements with the Investors which is conditional upon shareholders' approval. If Shareholder provides their authorization, the Convertible Notes will be issued in two tranches to provide an aggregate funded value of up to AU$8.0 million (AU$4.0 million in Tranche 1, and a further AU$4.0 million in Tranche 2 subject to mutual agreement between Lumos and the Investors).

The proceeds from the Convertible Note Agreements will support the Company into the first half of FY24 as it continues to focus on cash-generating activities within its development and services business units.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com